

Bristol Haemato-Oncology Diagnostic Service



Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS)

Pathology Sciences, North Bristol NHS Trust, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB Website: Haematological Malignancy Diagnostics (SIHMDS) | North Bristol NHS Trust (nbt.nhs.uk)

Flow lab: Flowlab@nbt.nhs.uk Tel. 0117 414 8377

Cellular pathology consultants: CellularPathologyHaemPathTeam1@nbt.nhs.uk

Celiulai		• Celidiair adiologyi ideilir adi i edili i @	HDC.HH5.UK					
PATIENT DETAILS								
Surname:	Given Name:	Originating Hospital	Consultant					
NHS Number:	Hospital Number:	Postcode	□NHS					
Turio ruanison	Troophar Hambor.	1 00.0000	☐ Private					
			Research					
Date of Birth:	Priority:	Previous investigation at	Known danger of infection					
☐ Male ☐ Female	☐ Urgent☐ Routine	BHODS? Yes / No	sample? Yes ☐ / No ☐					
SPECIMEN DETAILS								
Specimen type(s): tick all that apply Specimen Details:								
☐ Marrow aspirate								
☐ Marrow trephine	Biopsy site:							
Blood		☐ Relap)					
☐ Lymph Node ☐ Skin (germline)	Specimen date		up / MRD					
Saliva	Specimen time		r-up / IVIICD					
Other fluid / tissue	•							
Please specify								
CLINICAL DETAILS / SUSPECTED DIAGNOSIS:								
Details of relevant current/previous treatment:								
		Hb: Lympl	nocytes:					
		WBC: Platel	ets:					
		Neutrophils: Other						
	INIVECTIC	ATIONS DECLURED.						
		GATIONS REQUIRED: for specimen requirements						
Aspirate morphology - Further details:								
_ , , ,								
	4-11-							
Flow cytometry - Further de	Halls:							
Cytology / Cellular Pathology - Further details:								
O contract								
☐ Genetic Testing Please ensure BOTH SIDES of this request are completed and returned with genetics samples. Genetic testing will be								
undertaken according to the National Genomic Test Directory and, unless otherwise indicated, agreed diagnostic algorithms.								
REQUESTOR DETAILS:								
Specimen sent by:	Contact det	tails:						
In submitting this comple the of	inician confirms that as	onsent has been obtained to test for	the suspected disorder and for					
in submitting this sample the ci cellular/DNA/RNA storage. May			the suspected disorder and for					

GENOMIC TESTING: Further information on genomic testing is available from the <u>South West Genomic Laboratory Hub</u> and the <u>National Genomic Test Directory for Cancer.</u>						
Indication	Test	Sample	Indication	Test	Sample	
ALL[M91]	☐ Diagnosis/Relapse	A & B	MDS [M82]	☐ Karyotype [M82.2]	Α	
	☐ TPMT/NUDT15	В		SNP Array [M82.2]	В	
	☐ MRD Monitoring [M91.23]	В		☐ MDS gene panel [M82.1]	В	
	Other Monitoring:	В	MDS/MPN	☐ Karyotype [M224.2]	А	
			[M224]	☐ PDGFR FISH [M224.6]	Α	
				☐ RNA Fusion Panel [M224.6]	Α	
AML[M80]	☐ Diagnosis/Relapse	A & B		☐ MDS/MPN gene panel [M224.1]	В	
				☐ BCR-ABL1 [M224.10]		
	☐ APL (PML/RARA) [M80.29]	A & B		☐ JMML gene panel [M88.1]	В	
	☐ MLDS panel (<i>GATA1</i>) [M80.19]	A & B	MPN [M85]	☐ <i>JAK</i> 2(V617F) [M85.14]	В	
	☐ NPM1 Monitoring [M80.9]	В		☐ JAK2(ex12), CALR, MPL	В	
	☐ Monitoring (Specify target):	В		[M85.1]		
				☐ BCR-ABL1 [M85.11]	В	
				☐ MPN gene panel [M85.2]	В	
CLL [M94]	☐ IgVH [M94.5]	В		☐ Karyotype [M85.3]	Α	
				☐ RNA Fusion Panel [M85.7]	Α	
	☐ <i>TP53</i> (17p) deletion [M94.4] and mutation [M94.1]	A & B	1	☐ PDGFR FISH [M85.7]	Α	
CML [M84]	☐ BCR-ABL1 diagnosis [M84.1]	В	Myeloma [M92]	☐ FISH panel	Α	
	☐ BCR-ABL1 monitoring [M84.2]	В	SM [M86]	☐ KIT (D816V) [M86.2] ☐ SM panel [M224.1]	В	
	☐ BCR-ABL1 TKD NGS [M84.8]	В	Storage	☐ Cell suspension	Α	
	☐ Karyotype [M84.4]	Α		☐ Plasma cell enriched	Α	
				☐ DNA ☐ RNA	В	
				_	В	
CNL [M87]	☐ CSF3R [M87.1]	В	TAM [M81]	☐ <i>GATA1</i> [M81.1]	В	
HCL	☐ <i>BRAF</i> [M108.1]	В		Whole Genome Sequencing (WGS)*:		
LGL[M114]	[M114.1] ☐ WGS for TY/		☐ Acute Leukaer	nia	B & C	
			☐ WGS for TYA (≤25 years old)			
LPL [M104]	LPL panel (MYD88/CXCR4) [M104.1]	В	☐ WGS for proven or suspected haematological tumour exhausted all standard of care testing/treatment			

Test	Sample Requirements				
Morphology	Blood / Marrow aspirate samples; PB slides x2 + BM slides x3, PB 5ml in EDTA +/or BM Asp 2ml in EDTA				
Flow cytometry	Blood or bone marrow in EDTA				
Genetics	A) 5ml blood in Lithium Heparin/1-2ml BMA 1-2ml in heparinised tissue culture medium/ 1-2ml BMA in EDTA				
	B) 10-20ml blood/1-2ml BMA in EDTAx2				
	Samples for molecular monitoring and WGS to reach the lab within 72 hours				
	C) Skin biopsy for germline analysis, fresh (NOT fixed) sample in sterile saline to reach the lab within 72				
	hours.				
	Molecular and FISH testing is possible on formalin fixed, paraffin embedded tissue sections. Please contact				
	the laboratory for further details if required.				
	*WGS Tumour sample: FRESH (not fixed) sample with >30% tumour, <20% necrosis				
	Germline sample: skin (C) or remission (<0.1% MRD) blood/marrow (B)				
	Record of Discussion and Test Order form . Contact rde-tr.swgenomicpractitioner@nhs.net for further				
	information.				
Tissue/Other	Lymph node FNA for cytology: smear slides, needle washings in CytoLyt				
samples	Fresh tissue for flow cytometry and genetics: Saline or cell culture medium (without coagulation or				
	preservative). Please alert laboratory flowlab@nbt.nhs.uk tel: 0117 414 8377 NB Samples placed in Formalin				
	or CytoLyt (an alcohol preservative) cannot be used for flow cytometry				
	Lymphoreticular testing on formalin fixed paraffin embedded tissue (FFPE) should be requested using the				
	Cancer Genomics Request Form.				